Lung Cancer Treatment Demonstrates Favorable Safety Profile

French drugmaker Transgene reported data from a Phase IIb trial evaluating therapeutic vaccine TG4010 as an adjunct to first-line chemotherapy in patients with advanced nonsmall cell lung cancer.

The randomized, open-label, controlled study assessed the efficacy of TG4010 in combination with chemotherapy (cisplatin and gemcitabine) compared with chemotherapy alone.

The trial enrolled 148 patients who had not received prior treatment. Half received the combination regimen and the other half received chemotherapy alone.

TG4010 demonstrated a favorable safety profile, and data are expected by the fourth quarter of the year, Transgene said.